Medicenna Therapeutics Corp Market Cap ($25.04 Million)
Market Cap & Net Worth: Medicenna Therapeutics Corp (MDNA)
Medicenna Therapeutics Corp market cap. Medicenna Therapeutics Corp (TO:MDNA) has a market capitalization of $25.04 Million (CA$34.62 Million) as of November 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #24202 globally and #905 in its home market, demonstrating a -1.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medicenna Therapeutics Corp's stock price CA$0.42 by its total outstanding shares 83420201 (83.42 Million). Also see cash efficiency ratio of Medicenna Therapeutics Corp for how efficiently the company converts equity into cash flow.
Medicenna Therapeutics Corp Market Cap History (2015–2026)
Medicenna Therapeutics Corp market cap history from 2015 to 2026. Data shows growth from $3.92 Million to $25.04 Million (17.49% CAGR). Check Medicenna Therapeutics Corp (MDNA) share price today for real-time trading data and today's change.
Medicenna Therapeutics Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medicenna Therapeutics Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Medicenna Therapeutics Corp (MDNA) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MDNA by Market Capitalization
Companies near Medicenna Therapeutics Corp in the global market cap rankings as of November 4, 2026. Also see MDNA total asset value for a full breakdown of the balance sheet.
Key companies related to Medicenna Therapeutics Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Medicenna Therapeutics Corp (2015–2026)
Market capitalization of Medicenna Therapeutics Corp from 2015 to today. Between 2015 and today, Medicenna Therapeutics Corp's market cap moved from $3.92 Million to $ 25.04 Million, with a yearly change of 17.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$25.04 Million | -54.89% |
| 2025 | CA$55.52 Million | -44.24% |
| 2024 | CA$99.57 Million | +292.86% |
| 2023 | CA$25.34 Million | -34.38% |
| 2022 | CA$38.62 Million | -69.52% |
| 2021 | CA$126.72 Million | -64.71% |
| 2020 | CA$359.05 Million | +75.00% |
| 2019 | CA$205.17 Million | +385.71% |
| 2018 | CA$42.24 Million | -65.00% |
| 2017 | CA$120.69 Million | +1900.00% |
| 2016 | CA$6.03 Million | +53.85% |
| 2015 | CA$3.92 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Medicenna Therapeutics Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.04 Million USD |
| MoneyControl | $25.04 Million USD |
| MarketWatch | $25.04 Million USD |
| marketcap.company | $25.04 Million USD |
| Reuters | $25.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more